Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Children under five years of age, especially those aged two years or under, face a high risk of pneumococcal disease, which ...

Pneumococcal vaccines are the most effective way to protect yourself or your child against pneumococcal disease, and may help prevent infections including ear infections, pneumonia (lung infection ...

Sponsored by Pfizer - For actress and producer Elizabeth Banks, turning 50 meant prioritizing preventative care to stay strong and healthy — including staying ...

Healthcare providers, public health officials and policymakers need to develop a greater understanding of the serious health impact of pneumococcal disease in elderly adults. In addition to ...

With Capvaxive, MSD (known as Merck & Co in the US and Canada) is aiming to carve out a niche in the over-50s, positioning it as the go-to vaccine used to prevent invasive pneumococcal disease ...

EDT Vaxcyte (PCVX) sinks 35% to $45 after pneumococcal disease vaccine resultsDon't Miss Our End of Quarter Offers: Discover the latest ...

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

There are around 100 different pneumococcal serotypes, causing non-invasive disease like pneumonia, confined to the lungs, and invasive disease, where the infection can spread to the bloodstream ...

To get the word out about the expanded guidelines and the risk of pneumococcal disease, Pfizer this month launched a campaign focused on reaching the 50-plus crowd via social and digital channels ...

Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...